Farma ter Verantwoording

The Power of Law part II: webinar record & sheets

Looking back at last week's webinar

On 27 January we hosted the second part of our webinar series The Power of Law.

This second part was dedicated to presenting our recently published Guidelines for Legal Procedures by NGOs, which we illustrated with examples from practice.

Missed the webinar or want to listed back a part of the interesting discussions we had?

The webinar recording can be found here.

Please COunt on us for future legal action. we need to work together to build litigation theories

Peter Maybarduk, Public Citizen

Speakers presentations (and link to slides): 

As an inspirational break and to learn from other successful movements, we played a video on Friends of the Earth Netherlands (Milieudefensie) winning the climate case against Shell.

Links and comments shared through chat:

  • Patrick: In this CL model request for cancer drug pertuzumab prepared for Swiss authorities to submit to the patent court (2019), we used both competition law (excessive pricing) & patent law arguments.
  • Peter Maybarduk: Public Citizen also uses Freedom of Information (FOIA) requests, and then when consumer groups are turned down — as we often are, for example the govt will cite a national security exemption, far too broadly — then we litigate in the courts, to compel the govt to disclose documents under FOIA. (When we think we have a winning theory.) It’s a powerful but limited tool.
  • Peter Maybarduk: As the guidelines say, we begin by asking the company to act, then the govt through administrative requests – legal requests to the administrative state. When the government agencies refuse to act, we can go to the courts to compel action. For example,to defend the right to health. However, a challenge to this approach is that states aren’t usually obligated to spend money. And how do we think about the right to health? Is it indiivudal – in which cases, companies can fix a problem pretty easily, and avoid accountability, or is it collective?
  • And, Wilbert shared PAFs case of interest: AbbVie’s pricing strategy on Humira.

Related Articles

Articles by Category